American Journal of Epidemiology Advance Access originally published online on July 17, 2006
American Journal of Epidemiology 2006 164(6):567-575; doi:10.1093/aje/kwj250
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Contribution |
The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women
1 University of California, San Diego, CA
2 Los Angeles Biomedical Research Institute, Torrance, CA
3 Geisinger Health Systems, Danville, PA
4 Fred Hutchinson Cancer Research Center, Seattle, WA
5 Northwestern University, Chicago, IL
6 University of Pittsburgh, Pittsburgh, PA
Correspondence to Dr. Matthew Allison, 3855 Health Sciences Drive, La Jolla, CA 92093-0817 (e-mail: mallison{at}ucsd.edu).
The purpose of this study was to test the hypothesis that aspirin use is associated with a decreased risk of incident colorectal cancer. From the Women's Health Initiative, 91,574 participants between the ages of 50 and 79 years at baseline in 1993–1998 provided details on aspirin use via interview using a standardized questionnaire and were subsequently followed annually for incident colorectal cancer during a period of over 6 years. For those persons who reported aspirin use, the type of compound, dose, and duration of use were recorded. Medical histories suggestive of colorectal cancers at the annual update were verified by medical record and pathology report review by trained local physician adjudicators. There were 631 confirmed cases of invasive cancer of the colon or rectum. There was no significant association between any aspirin use and risk for incident colorectal cancer (hazard ratio = 0.96, 95% confidence interval: 0.8, 1.2). Moreover, with no aspirin use as the referent category, there were no significant associations for duration of aspirin intake by category (<1, 1–<2, 2–<3, 3–<4, 4–<5, and 
5 years) or for daily dosage by category (<165, 165–<300, 300–<495, or 495 mg).
aspirin; colonic neoplasms; primary prevention; rectal neoplasms
Abbreviations: CI, confidence interval; HR, hazard ratio; NSAID, nonsteroidal antiinflammatory drug; SEER, Surveillance, Epidemiology, and End Results
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Bardia, J. O. Ebbert, R. A. Vierkant, P. J. Limburg, K. Anderson, A. H. Wang, J. E. Olson, C. M. Vachon, and J. R. Cerhan Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality J Natl Cancer Inst, June 6, 2007; 99(11): 881 - 889. [Abstract] [Full Text] [PDF]
|
|